Abstract
Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD, discussed the indications for the three PARP agents (olaparib, rucaparib, and niraparib) and strategies for managing PARP inhibitor–related side effects.
Sequencing of Treatments for Patients With Ovarian Cancer
April 22, 2019
Volume 10, Number 3 (Apr 2019)
https://doi.org/10.6004/jadpro.2019.10.3.11
